Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Total 13F shares
-
93,427,423
-
Share change
-
+17,775,030
-
Total reported value
-
$138,270,175
-
Put/Call ratio
-
0%
-
Price per share
-
$1.48
-
Number of holders
-
113
-
Value change
-
+$26,564,144
-
Number of buys
-
43
-
Number of sells
-
42
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q1 2024
As of 31 Mar 2024,
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) was held by
113 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
93,427,423 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, BlackRock Inc., VANGUARD GROUP INC, Logos Global Management LP, Defender Capital, LLC., GEODE CAPITAL MANAGEMENT, LLC, RAFFLES ASSOCIATES LP, STATE STREET CORP, Prescott General Partners LLC, and MAI Capital Management.
This page lists
113
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.